Michael Varney - Roche Holding Executive
RHHBF Stock | USD 254.50 8.50 3.23% |
Executive
Dr. Michael David Varney, Ph.D., was Member of the Enlarged Corporationrationrate Executive Committee, Head Genentech Research Early Development at Roche Holding Ltd since 2015. He holds BS degree form University of California, Los Angeles and a Ph.D. from California Institute of Technology . From 1985 to 1987 he was Postdoctoral Research Fellow at the Columbia University. In 1987 he joined Agouron Pharmaceuticals Inc., where he served until 2000 and held such positions as Research Chemist, Director Medicinal Chemistry, Senior Director of Chemistry, Senior Director of Drug Discovery, Vice President and Head of Research as well as US, Corporationrationrate Vice President, Head of Research. From 2000 to 2005 he served at Pfizer Global RD as Vice President, Drug Discovery. In 2005 he joined Genentech Inc., where he acted as Vice President of Small Molecule Drug Discovery, Senior Vice President, Research of Small Molecule Drug Discovery and Senior Vice President, CoHead of Research and Head Small Molecule Discovery. since 2015.
Age | 60 |
Tenure | 9 years |
Professional Marks | Ph.D |
Phone | 41 61 688 11 11 |
Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Eva Tubau | Grifols SA ADR | N/A | |
John Reed | Roche Holding Ltd | 59 | |
Karl Mahler | Roche Holding Ltd | N/A | |
Vicente Torre | Grifols SA ADR | 63 | |
Urs Jaisli | Roche Holding Ltd | 62 | |
Sophie KornowskiBonnet | Roche Holding Ltd | 54 | |
Silvia Ayyoubi | Roche Holding Ltd | 62 | |
Nuria Barnes | Grifols SA ADR | N/A | |
James Sabry | Roche Holding Ltd | 59 | |
F Hoffmann | Roche Holding Ltd | N/A | |
Montserrat Calvo | Grifols SA ADR | N/A | |
M Tubau | Grifols SA ADR | N/A | |
Stephan Feldhaus | Roche Holding Ltd | 56 | |
Alan Hippe | Roche Holding Ltd | 56 | |
William Pao | Roche Holding Ltd | 51 | |
Cristina Wilbur | Roche Holding Ltd | 56 | |
Raimon Roura | Grifols SA ADR | 60 | |
Gottlieb Keller | Roche Holding Ltd | 64 |
Management Performance
Return On Equity | 0.45 | |||
Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications | ||
Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
Bruno Eschli, Head Relations | ||
Silvia Ayyoubi, Head of Group HR | ||
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
Thomas Schinecker, Chief Diagnostics | ||
Beatrice Mauro, Non-Executive Director | ||
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
Gottlieb Keller, General Counsel and Corporate Secretary | ||
Urs Jaisli, Chief Compliance Officer | ||
Daniel ODay, COO of Pharmaceuticals division | ||
Claudia Bockstiegel, G Counsel | ||
DeAnne Julius, Non-Executive Director | ||
Johannes MD, Head Devel | ||
Karl Mahler, Head of Investor Relations | ||
Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
Claudia Dyckerhoff, Non-Executive Director | ||
Fritz Gerber, Honorary Chairman of the Board | ||
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
Julie Brown, Non-Executive Director | ||
Richard Lifton, Non-Executive Director | ||
Paul Bulcke, Non-Executive Director | ||
Christoph Franz, Non-Executive Director | ||
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
Pascale Schmidt, Chief Officer | ||
Pius Baschera, Non-Executive Director | ||
Peter Voser, Non-Executive Director | ||
Bernard Poussot, Non-Executive Director | ||
John Bell, Non-Executive Director | ||
Andreas Oeri, Non-Executive Director | ||
Alan Hippe, CFO and IT Officer | ||
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
F Hoffmann, IR Contact Officer | ||
Severin Schwan, CEO and Director | ||
Anita Hauser, Non-Executive Director | ||
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.45 | |||
Return On Asset | 0.15 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.32 % | |||
Current Valuation | 287.91 B | |||
Shares Outstanding | 106.69 M | |||
Shares Owned By Insiders | 75.31 % | |||
Shares Owned By Institutions | 8.56 % | |||
Price To Earning | 21.63 X | |||
Price To Book | 11.61 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Roche Holding AG information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Stocks Directory Find actively traded stocks across global markets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |